Stock Analysis

Aurora Cannabis Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St

June 24, 2024

Aurora Cannabis (TSE:ACB) Full Year 2024 Results

Key Financial Results

Revenue: CA$270.3m (up 21% from FY 2023).
Net loss: CA$55.3m (loss narrowed by 93% from FY 2023).
CA$1.28 loss per share (improved from CA$26.06 loss in FY 2023).

revenue-and-expenses-breakdown — TSX:ACB Revenue and Expenses Breakdown June 24th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aurora Cannabis EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.9%.

The primary driver behind last 12 months revenue was the Cannabis segment contributing a total revenue of CA$225.5m (83% of total revenue). Notably, cost of sales worth CA$138.8m amounted to 51% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CA$104.9m (56% of total expenses). Explore how ACB's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada.

Performance of the Canadian Pharmaceuticals industry.

The company's shares are down 11% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Aurora Cannabis you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether Aurora Cannabis is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.